124 related articles for article (PubMed ID: 17906705)
1. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
Magagnoli M; Spina M; Balzarotti M; Timofeeva I; Isa L; Michieli M; Capizzuto R; Morenghi E; Castagna L; Tirelli U; Santoro A
Bone Marrow Transplant; 2007 Dec; 40(11):1019-25. PubMed ID: 17906705
[TBL] [Abstract][Full Text] [Related]
2. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.
Magagnoli M; Sarina B; Balzarotti M; Castagna L; Timofeeva I; Nozza A; Bertuzzi A; Siracusano L; Sinnone M; Santoro A
Bone Marrow Transplant; 2001 Nov; 28(10):923-7. PubMed ID: 11753545
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
5. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Castagna L; Magagnoli M; Balzarotti M; Sarina B; Siracusano L; Nozza A; Todisco E; Bramanti S; Mazza R; Russo F; Timofeeva I; Santoro A
Am J Hematol; 2007 Feb; 82(2):122-7. PubMed ID: 17019686
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.
Marr K; Ronsley R; Nadel H; Douglas K; Gershony S; Strahlendorf C; Davis JH; Deyell RJ
Pediatr Blood Cancer; 2020 Apr; 67(4):e28167. PubMed ID: 31925920
[TBL] [Abstract][Full Text] [Related]
8. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
9. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
10. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
12. Which regimen is better for stem cell mobilization of lymphoma patients?
Bozdağ SC; Tekgündüz E; Durgun G; Sarıca A; Demiriz IŞ; Koçubaba S; Altuntaş F
Transfus Apher Sci; 2013 Jun; 48(3):407-10. PubMed ID: 23643475
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
14. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
[TBL] [Abstract][Full Text] [Related]
15. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma.
Heizmann M; O'Meara AC; Moosmann PR; Heijnen IA; Zuberbühler M; Fernandez P; Burger J; Huber A; Wernli M; Bargetzi MJ
Bone Marrow Transplant; 2009 Jul; 44(2):75-9. PubMed ID: 19169288
[TBL] [Abstract][Full Text] [Related]
16. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
Smardova L; Engert A; Haverkamp H; Raemakers J; Baars J; Pfistner B; Diehl V; Josting A
Leuk Lymphoma; 2005 Jul; 46(7):1017-22. PubMed ID: 16019552
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
18. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
20. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
Calandra G; McCarty J; McGuirk J; Tricot G; Crocker SA; Badel K; Grove B; Dye A; Bridger G
Bone Marrow Transplant; 2008 Feb; 41(4):331-8. PubMed ID: 17994119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
